首页> 美国卫生研究院文献>World Journal of Diabetes >Diabetic retinopathy - ocular complications of diabetes mellitus
【2h】

Diabetic retinopathy - ocular complications of diabetes mellitus

机译:糖尿病性视网膜病变-糖尿病的眼部并发症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In industrialized nations diabetic retinopathy is the most frequent microvascular complication of diabetes mellitus and the most common cause of blindness in the working-age population. In the next 15 years, the number of patients suffering from diabetes mellitus is expected to increase significantly. By the year 2030, about 440 million people in the age-group 20-79 years are estimated to be suffering from diabetes mellitus worldwide (prevalence 7.7%), while in 2010 there were 285 million people with diabetes mellitus (prevalence 6.4%). This accounts for an increase in patients with diabetes in industrialized nations by 20% and in developing countries by 69% until the year 2030. Due to the expected rise in diabetic patients, the need for ophthalmic care of patients (i.e., exams and treatments) will also increase and represents a challenge for eye-care providers. Development of optimized screening programs, which respect available resources of the ophthalmic infrastructure, will become even more important. Main reasons for loss of vision in patients with diabetes mellitus are diabetic macular edema and proliferative diabetic retinopathy. Incidence or progression of these potentially blinding complications can be greatly reduced by adequate control of blood glucose and blood pressure levels. Additionally, regular ophthalmic exams are mandatory for detecting ocular complications and initiating treatments such as laser photocoagulation in case of clinical significant diabetic macular edema or early proliferative diabetic retinopathy. In this way, the risk of blindness can considerably be reduced. In advanced stages of diabetic retinopathy, pars-plana vitrectomy is performed to treat vitreous hemorrhage and tractional retinal detachment. In recent years, the advent of intravitreal medication has improved therapeutic options for patients with advanced diabetic macular edema.
机译:在工业化国家,糖尿病性视网膜病是糖尿病最常见的微血管并发症,也是劳动年龄人群失明的最常见原因。在未来的15年中,预计患有糖尿病的患者人数将大大增加。到2030年,估计20-79岁年龄段的全世界约有4.4亿人患有糖尿病(患病率为7.7%),而2010年则有2.85亿糖尿病人(患病率为6.4%)。到2030年,工业化国家的糖尿病患者将增加20%,发展中国家的糖尿病患者将增加69%。由于糖尿病患者的预期增加,因此需要对患者进行眼科护理(即检查和治疗)还将增加,这对眼保健提供者构成了挑战。尊重眼科基础设施可用资源的优化检查程序的开发将变得更加重要。糖尿病患者视力下降的主要原因是糖尿病性黄斑水肿和增生性糖尿病视网膜病变。通过适当控制血糖和血压水平,可以大大减少这些潜在致盲并发症的发生或发展。另外,在临床上明显的糖尿病性黄斑水肿或早期增生性糖尿病性视网膜病的情况下,必须定期进行眼科检查以检测眼部并发症并开始治疗,例如激光光凝。这样,可以大大降低失明的风险。在糖尿病性视网膜病的晚期,进行pars-plana玻璃体切除术可治疗玻璃体出血和牵引性视网膜脱离。近年来,玻璃体内药物的出现改善了晚期糖尿病性黄斑水肿患者的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号